Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.
Buisseret L, Garaud S, de Wind A, Van den Eynden G, Boisson A, Solinas C, Gu-Trantien C, Naveaux C, Lodewyckx JN, Duvillier H, Craciun L, Veys I, Larsimont D, Piccart-Gebhart M, Stagg J, Sotiriou C, Willard-Gallo K. Buisseret L, et al. Oncoimmunology. 2016 Dec 14;6(1):e1257452. doi: 10.1080/2162402X.2016.1257452. eCollection 2017. Oncoimmunology. 2016. PMID: 28197375 Free PMC article.
Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M. Solinas C, et al. Among authors: buisseret l. Cancer Treat Rev. 2017 Jun;57:8-15. doi: 10.1016/j.ctrv.2017.04.005. Epub 2017 May 2. Cancer Treat Rev. 2017. PMID: 28525810 Review.
Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.
Buisseret L, Desmedt C, Garaud S, Fornili M, Wang X, Van den Eyden G, de Wind A, Duquenne S, Boisson A, Naveaux C, Rothé F, Rorive S, Decaestecker C, Larsimont D, Piccart-Gebhart M, Biganzoli E, Sotiriou C, Willard-Gallo K. Buisseret L, et al. Mod Pathol. 2017 Sep;30(9):1204-1212. doi: 10.1038/modpathol.2017.43. Epub 2017 Jun 16. Mod Pathol. 2017. PMID: 28621322 Free article.
Targeting immune checkpoints in breast cancer: an update of early results.
Solinas C, Gombos A, Latifyan S, Piccart-Gebhart M, Kok M, Buisseret L. Solinas C, et al. Among authors: buisseret l. ESMO Open. 2017 Nov 14;2(5):e000255. doi: 10.1136/esmoopen-2017-000255. eCollection 2017. ESMO Open. 2017. PMID: 29177095 Free PMC article. Review.
Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.
Garaud S, Buisseret L, Solinas C, Gu-Trantien C, de Wind A, Van den Eynden G, Naveaux C, Lodewyckx JN, Boisson A, Duvillier H, Craciun L, Ameye L, Veys I, Paesmans M, Larsimont D, Piccart-Gebhart M, Willard-Gallo K. Garaud S, et al. Among authors: buisseret l. JCI Insight. 2019 Aug 13;5(18):e129641. doi: 10.1172/jci.insight.129641. JCI Insight. 2019. PMID: 31408436 Free PMC article.
Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.
De Caluwé A, Buisseret L, Poortmans P, Van Gestel D, Salgado R, Sotiriou C, Larsimont D, Paesmans M, Craciun L, Stylianos D, Vandekerckhove C, Reyal F, Isabelle V, Eiger D, Piccart M, Romano E, Ignatiadis M. De Caluwé A, et al. Among authors: buisseret l. BMC Cancer. 2021 Aug 6;21(1):899. doi: 10.1186/s12885-021-08601-1. BMC Cancer. 2021. PMID: 34362344 Free PMC article. Clinical Trial.
Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer.
Agostinetto E, Jacobs F, Debien V, De Caluwé A, Pop CF, Catteau X, Aftimos P, de Azambuja E, Buisseret L. Agostinetto E, et al. Among authors: buisseret l. Cancers (Basel). 2022 Nov 7;14(21):5467. doi: 10.3390/cancers14215467. Cancers (Basel). 2022. PMID: 36358886 Free PMC article. Review.
42 results